Novo Nordisk A/S (NVO)
Positive Development
Today Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
The Wegovy® pill approval is a landmark moment in the treatment of obesity in Europe, making it the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states. It marks the fifth regulatory approval of Wegovy® pill, after the US, UK, UAE and Bahrain.
This is an important milestone given that the oral Wegovy launch has been successful. Since Lilly's GLP-1 pill (Foundayo) hit the market in April, Lilly has captured ~11% of the Rx volume for new pills, while Novo's Wegovy pill has captured 89%.